NASDAQ:GNVC

163741 Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$7.19
0.00 (0.00 %)
(As of 06/26/2017)
Add
Today's Range
$7.19
Now: $7.19
$7.19
50-Day Range N/A
52-Week Range
$2.70
Now: $7.19
$10.44
VolumeN/A
Average Volume259,136 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
163741 logo

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:GNVC
CUSIPN/A
Phone+1-240-6320740
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Receive GNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for GNVC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











163741 (NASDAQ:GNVC) Frequently Asked Questions

What stocks does MarketBeat like better than 163741?

Wall Street analysts have given 163741 a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but 163741 wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were 163741's earnings last quarter?

163741 (NASDAQ:GNVC) released its earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.07 million.
View 163741's earnings history
.

When did 163741's stock split? How did 163741's stock split work?

Shares of 163741 reverse split on the morning of Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2016. An investor that had 100 shares of 163741 stock prior to the reverse split would have 10 shares after the split.

Who are 163741's key executives?

163741's management team includes the following people:
  • Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
  • Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
  • William N. Kelley M.D., Independent Director
  • Stefan D. Loren Ph.D., Independent Director
  • Quinterol J. Mallette M.D., Independent Director
  • Michael S. Richman, Independent Director
  • Marc R. Schneebaum, Independent Director

What other stocks do shareholders of 163741 own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 163741 investors own include Sarepta Therapeutics (SRPT), Alibaba Group (BABA), (CKG) (CKG), NVE (NVEC), Microbot Medical (MBOT), Pluristem Therapeutics (PSTI), Acer Therapeutics (ACER), Chesapeake Energy (CHKAQ), MicroVision (MVIS) and 369807 (SGY).

What is 163741's stock symbol?

163741 trades on the NASDAQ under the ticker symbol "GNVC."

What is 163741's stock price today?

One share of GNVC stock can currently be purchased for approximately $7.19.

What is 163741's official website?

The official website for 163741 is www.genvec.com.

Where are 163741's headquarters?

163741 is headquartered at 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States.

How can I contact 163741?

163741's mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company can be reached via phone at +1-240-6320740.


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.